Congress Watch archives 2022

From ESMO Congress 2022:
Use of enzalutamide alongside abiraterone plus steroids and androgen deprivation therapy does not further improve overall survival of metastatic hormone-sensitive prostate cancer

From ESMO Congress 2022:
Camrelizumab plus rivoceranib may significantly extend survival compared with sorafenib for patients with previously untreated unresectable or metastatic hepatocellular carcinoma

From ESMO Congress 2022:
Patients with resectable stage IIIB–IVM1a melanoma derive a survival benefit from receipt of talimogene laherparepvec treatment before surgery

From the World Conference on Lung Cancer 2022:
Around a fifth of patients with thoracic cancer die within 30 days of COVID-19 infection but the risk is not predicted by recent receipt of systematic treatment for their malignancy

From the World Conference on Lung Cancer 2022:
Some participants of the KEYNOTE-604 trial with extensive-stage small-cell lung cancer have derived long-term survival benefits from the use of pembrolizumab plus etoposide

From the World Conference on Lung Cancer 2022:
NADIM II shows combining neoadjuvant chemotherapy with nivolumab before and after surgery improves progression-free and overall survival in resectable stage IIIA–B non-small-cell lung cancer

From the World Conference on Lung Cancer 2022:
Interim overall survival results show a trend in favour of adjuvant atezolizumab for NSCLC patients with stage II–IIIA, PD-L1-positive disease

From the World Conference on Lung Cancer 2022:
Use of sugemalimab versus placebo after receipt of chemoradiotherapy significantly improves progression-free survival in patients with stage III unresectable non-small-cell lung cancer

From the World Conference on Lung Cancer 2022:
Lead-in sotorasib monotherapy followed by the addition of pembrolizumab has shown early promise for the treatment of advanced KRAS G12C-mutated NSCLC

From EAU 2022:
A database analysis suggests that overall survival may be adversely affected by the presence of pelvic lymphadenopathy in patients with stage N3 penile squamous cell cancer

From EAU 2022
Relugolix achieves profound castration faster than leuprolide for men with advanced prostate cancer and maintains this benefit for longer

From EAU 2022:
The STORM trial has found comparable acute toxicity with metastasis-directed therapy and a whole-pelvis radiotherapy regimen for men with oligorecurrent nodal prostate cancer